logo

For the Inventor, By the Inventor

Kyriacos Costa Nicolaou

La Jolla, CA, United States of America

Kyriacos Costa Nicolaou

USPTO Granted Patents = 60 

 

Average Co-Inventor Count = 3.5

ph-index = 12

Forward Citations = 576(Granted Patents)

Forward Citations (Not Self Cited) = 553(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Philadelphia, PA (US) (1981)
  • Haverton, PA (US) (1984 - 1986)
  • Havertown, PA (US) (1981 - 1993)
  • La Jolla, CA (US) (1992 - 2020)
  • Houston, TX (US) (2017 - 2023)

Company Filing History:

goldMedal32 out of 1,187 
 
The Scripps Research Institute
 patents
silverMedal11 out of 635 
 
William Marsh Rice University
 patents
bronzeMedal10 out of 444 
 
Research, Incorporated
 patents
4. 7 out of 2,622 
 
University of Pennsylvania
 patents
5. 3 out of 3,685 
 
Bristol-Myers Squibb Compnay
 patents
6. 2 out of 988 
 
Emory University
 patents
7. 2 out of 122 
 
Scripps Clinic and Research Foundation
 patents
8. 1 out of 2,202 
 
The United States of America as Represented by the Secretary of
 patents
9. 1 out of 832,880 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Anticancer Agents
Epothilone Derivatives
Dynemicin Analogs
Synthesis Techniques
HIF Inhibitors
Carbopeptoids
Taxol Transformations
Sarcodictyin Analogs
Onium Salts
Non-Peptide Peptidomimetics
Trioxacarcin Analogues
Chemical Synthesis
60 patents (USPTO):Explore Patents
1. 11584754 - Derivatives of thailanstatin A, methods of treatment and methods of synthesis thereof (2023-02-21),
2. 11465997 - Synthesis of disorazoles and analogs thereof as potent anticancer agents (2022-10-11),
3. 11274124 - Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith (2022-03-15),
4. 10899773 - Total synthesis of trioxacarcin DC-45-A2 and preparation of trioxacarcin analogs (2021-01-26),
5. 10889590 - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents (2021-01-12),
6. 10874646 - Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof (2020-12-29),
7. 10870670 - Preparation of (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside (2020-12-22),
8. 10808007 - Desacetoxytubulysin H and analogs thereof (2020-10-20),
9. 10590158 - Total synthesis of shishijimicin A and analogs thereof (2020-03-17),
10. 10233192 - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents (2019-03-19),
11. 10065924 - Preparation and biological evaluation of viridicatumtoxin analogs (2018-09-04),
12. 10030040 - Preparation of (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside (2018-07-24),
13. 9777013 - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents (2017-10-03),
14. 8071795 - HIF inhibitors (2011-12-06),
15. 8003801 - Chemical synthesis of a highly potent epothilone (2011-08-23),

Title: The Innovative Journey of Kyriacos Costa Nicolaou

Introduction:

Kyriacos Costa Nicolaou, a distinguished inventor based in La Jolla, CA, has made significant contributions to the field of chemistry and pharmaceuticals through his groundbreaking work.

Latest Patents:

Nicolaou's latest patents focus on novel methods for synthesizing complex natural products with potential therapeutic applications, showcasing his ongoing commitment to innovation in drug discovery.

Career Highlights:

With a career spanning several decades, Nicolaou has held prominent positions at esteemed research institutions and pharmaceutical companies, where he has led numerous successful projects resulting in the development of life-saving medications.

Collaborations:

Throughout his career, Nicolaou has collaborated with leading scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge-sharing within the scientific community.

Conclusion:

Kyriacos Costa Nicolaou's relentless pursuit of scientific excellence and his passion for pushing the boundaries of chemical synthesis have solidified his reputation as a pioneering inventor in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…